Collegium Pharmaceutical, Inc.

Greetings and welcome to the Collegium Pharmaceutical first quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during this conference, please press star zero on your telephone keypad. Please note that this conference call is being recorded. I will now turn the call over to Christopher James, Vice President of Investor Relations at Collegium. Thank you. You may begin.

Welcome to Collegium Pharmaceuticals' first quarter 2024 earnings conference call. I'm joined today by Joe Schifoni, our Chief Executive Officer, Colleen Tupper, our Chief Financial Officer, and Scott Dreyer, our Chief Commercial Officer. Mike Heffernan, the Chairman of our board, will join us for the Q&A portion of the call. Before we begin today's call, we want to remind participants that none of the information presented today is intended to be promotional, and that any forward-looking statements made today are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. You are cautioned that such forward-looking statements involve risk and uncertainties, including and without limitation, the risk that we may not be able to successfully commercialize our products, that we may incur significant expense in doing so, and that we may not prevail in current or future litigation pertaining to our business. These risks and other risks of the company are detailed in the company's periodic reports filed with the Securities and Exchange Commission. Our future results may differ materially from our current expectations discussed today. Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations, on our corporate website at collegianpharma.com. I will now turn the call over to our CEO, Joe Schifoni.

Thank you, Chris. Good afternoon and thank you everyone for joining the call. Today we will discuss our financial performance during the first quarter and provide an update on our progress in 2024. At Collegium, we are focused on building a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. We strive to do good as we do well. During the first quarter, in support of our commitment to increase equitable access to STEM education and advance the next generation of life science leaders, we selected the first participants in the Collegium Pharmaceutical Scholarship Program. This new program awards two scholarships to high school seniors pursuing a STEM-related major at a U.S. university. Additionally, at our 2024 National Sales Meeting, We built wagons filled with toys for Nicholas Children's Hospital in Miami, and we began the second year of our partnership with the Boston Red Sox and Science from Scientists. I'd like to recognize the Collegium team for their commitment to our mission and dedication to making a positive impact in the communities we serve. We are encouraged by the strong start to the year. 2024 is on track to be another record year for Collegium as we focus on operational execution to grow our core business and deploying capital to create value for our shareholders. Looking beyond 2024, key accomplishments across the Payne portfolio, including growing momentum for Bell Buca, a successful contracting strategy for Xtamsa ER, and the recently announced authorized generic agreement for the Nusenta franchise meaningfully improve our outlook for 2025 and beyond. I am proud of the success that the Collegium team has achieved over the years. We've delivered consistently strong financial performance with a track record of growing the top and bottom line, executing value-creating acquisitions, and being good stewards of capital. Collegium has an exceptional company culture with a team committed to making a positive impact on the communities we serve. With a healthy balance sheet, disciplined capital deployment strategy, and strong leadership, the company is well positioned for future growth. Earlier today, we announced that I will be stepping down as President and Chief Executive Officer of the company. To ensure a seamless transition, Mike Heffernan will serve as interim president and CEO until a new CEO is appointed. Mike founded Collegium in 2002, served as president and CEO for over 15 years, and is currently the chairman of our board. Given his past leadership at Collegium, he is well suited to lead the company during this transition period. It has been a privilege to work with many talented and dedicated colleagues at Collegium. and I am extremely proud of all that we have accomplished together. Collegium is in a strong position, both financially and strategically, and I'm confident that we have the right leadership team in place to advance the business forward. I will now hand the call over to Colleen to discuss business highlights and financials.